BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 27357540)

  • 1. Killing Glioma 'Stem-like' Cells via Drug-Induced Relocation of Endosomal Urokinase Proteins.
    Gorin FA; Pasupuleti N; Mahajan D; Dugar S
    Anticancer Agents Med Chem; 2017; 17(1):40-47. PubMed ID: 27357540
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mis-trafficking of endosomal urokinase proteins triggers drug-induced glioma nonapoptotic cell death.
    Pasupuleti N; Grodzki AC; Gorin F
    Mol Pharmacol; 2015 Apr; 87(4):683-96. PubMed ID: 25634671
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 5-Benzylglycinyl-amiloride kills proliferating and nonproliferating malignant glioma cells through caspase-independent necroptosis mediated by apoptosis-inducing factor.
    Pasupuleti N; Leon L; Carraway KL; Gorin F
    J Pharmacol Exp Ther; 2013 Mar; 344(3):600-15. PubMed ID: 23241369
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dual-targeting Wnt and uPA receptors using peptide conjugated ultra-small nanoparticle drug carriers inhibited cancer stem-cell phenotype in chemo-resistant breast cancer.
    Miller-Kleinhenz J; Guo X; Qian W; Zhou H; Bozeman EN; Zhu L; Ji X; Wang YA; Styblo T; O'Regan R; Mao H; Yang L
    Biomaterials; 2018 Jan; 152():47-62. PubMed ID: 29107218
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A new 2-pyrone derivative, 5-bromo-3-(3-hydroxyprop-1-ynyl)-2H-pyran-2-one, suppresses stemness in glioma stem-like cells.
    Kim RK; Kim MJ; Yoon CH; Lim EJ; Yoo KC; Lee GH; Kim YH; Kim H; Jin YB; Lee YJ; Cho CG; Oh YS; Gye MC; Suh Y; Lee SJ
    Mol Pharmacol; 2012 Sep; 82(3):400-7. PubMed ID: 22648970
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A novel drug conjugate, NEO212, targeting proneural and mesenchymal subtypes of patient-derived glioma cancer stem cells.
    Jhaveri N; Agasse F; Armstrong D; Peng L; Commins D; Wang W; Rosenstein-Sisson R; Vaikari VP; Santiago SV; Santos T; Chen L; Schönthal AH; Chen TC; Hofman FM
    Cancer Lett; 2016 Feb; 371(2):240-50. PubMed ID: 26683773
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Synthesis and preliminary evaluation of amiloride analogs as inhibitors of the urokinase-type plasminogen activator (uPA).
    Matthews H; Ranson M; Tyndall JD; Kelso MJ
    Bioorg Med Chem Lett; 2011 Nov; 21(22):6760-6. PubMed ID: 21978672
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Wound-induced migration of MDA-MB-435 and SKOV-3 cancer cells is regulated by plasminogen activator inhibitor-1.
    Whitley BR; Church FC
    Int J Oncol; 2005 Sep; 27(3):749-57. PubMed ID: 16077925
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anthocyanidins inhibit migration of glioblastoma cells: structure-activity relationship and involvement of the plasminolytic system.
    Lamy S; Lafleur R; Bédard V; Moghrabi A; Barrette S; Gingras D; Béliveau R
    J Cell Biochem; 2007 Jan; 100(1):100-11. PubMed ID: 16823770
    [TBL] [Abstract][Full Text] [Related]  

  • 10. siRNA targeting stathmin inhibits invasion and enhances chemotherapy sensitivity of stem cells derived from glioma cell lines.
    Song Y; Mu L; Han X; Liu X; Fu S
    Acta Biochim Biophys Sin (Shanghai); 2014 Dec; 46(12):1034-40. PubMed ID: 25348735
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibitors of urokinase reduce size of prostate cancer xenografts in severe combined immunodeficient mice.
    Jankun J; Keck RW; Skrzypczak-Jankun E; Swiercz R
    Cancer Res; 1997 Feb; 57(4):559-63. PubMed ID: 9044824
    [TBL] [Abstract][Full Text] [Related]  

  • 12. New advances of microRNAs in glioma stem cells, with special emphasis on aberrant methylation of microRNAs.
    Zhao B; Bian EB; Li J; Li J
    J Cell Physiol; 2014 Sep; 229(9):1141-7. PubMed ID: 24374932
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical relevance of urokinase-type plasminogen activator, its receptor, and its inhibitor type 1 in endometrial cancer.
    Tecimer C; Doering DL; Goldsmith LJ; Meyer JS; Abdulhay G; Wittliff JL
    Gynecol Oncol; 2001 Jan; 80(1):48-55. PubMed ID: 11136569
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Molecular basis of specific inhibition of urokinase plasminogen activator by amiloride.
    Jankun J; Skrzypczak-Jankun E
    Cancer Biochem Biophys; 1999 Jul; 17(1-2):109-23. PubMed ID: 10738907
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Expression of antisense uPAR and antisense uPA from a bicistronic adenoviral construct inhibits glioma cell invasion, tumor growth, and angiogenesis.
    Gondi CS; Lakka SS; Yanamandra N; Siddique K; Dinh DH; Olivero WC; Gujrati M; Rao JS
    Oncogene; 2003 Sep; 22(38):5967-75. PubMed ID: 12955075
    [TBL] [Abstract][Full Text] [Related]  

  • 16. uPA and PAI-1 as biomarkers in breast cancer: validated for clinical use in level-of-evidence-1 studies.
    Duffy MJ; McGowan PM; Harbeck N; Thomssen C; Schmitt M
    Breast Cancer Res; 2014 Aug; 16(4):428. PubMed ID: 25677449
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunohistochemical localization of urokinase-type plasminogen activator, type-1 plasminogen-activator inhibitor, urokinase receptor and alpha(2)-macroglobulin receptor in human breast carcinomas.
    Christensen L; Wiborg Simonsen AC; Heegaard CW; Moestrup SK; Andersen JA; Andreasen PA
    Int J Cancer; 1996 May; 66(4):441-52. PubMed ID: 8635858
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Binding areas of urokinase-type plasminogen activator-plasminogen activator inhibitor-1 complex for endocytosis receptors of the low-density lipoprotein receptor family, determined by site-directed mutagenesis.
    Skeldal S; Larsen JV; Pedersen KE; Petersen HH; Egelund R; Christensen A; Jensen JK; Gliemann J; Andreasen PA
    FEBS J; 2006 Nov; 273(22):5143-59. PubMed ID: 17042782
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Enhanced benefit from adjuvant chemotherapy in breast cancer patients classified high-risk according to urokinase-type plasminogen activator (uPA) and plasminogen activator inhibitor type 1 (n = 3424).
    Harbeck N; Kates RE; Look MP; Meijer-Van Gelder ME; Klijn JG; Krüger A; Kiechle M; Jänicke F; Schmitt M; Foekens JA
    Cancer Res; 2002 Aug; 62(16):4617-22. PubMed ID: 12183417
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of N-(4-hydroxyphenyl) retinamide on urokinase-type plasminogen activator and plasminogen activator inhibitor-1 in prostate adenocarcinoma cell lines.
    Tanabe T
    Hiroshima J Med Sci; 2000 Mar; 49(1):67-72. PubMed ID: 10824459
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.